Elsevier

Hepatology

Volume 21, Issue 1, January 1995, Pages 77-82
Hepatology

Other clinical study
Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B

https://doi.org/10.1016/0270-9139(95)90411-5Get rights and content

Abstract

To examine the morbidity of compensated cirrhosis type B, a cohort of 349 Western European, white patients (86% men; mean age, 44 years) with biopsy-proven cirrhosis was followed up for a mean period of 73 months and was studied for occurrence of hepatocellular carcinoma (HCC) and decompensation. At entry into the study all patients were tested for hepatitis B e antigen (HBeAg; 34% of patients were HBeAg-positive) and antibody to hepatitis delta virus (anti-HDV; 20% of patients were anti-HDV-positive); 48% of 252 patients tested were hepatitis B virus (HBV)-DNA-positive. During follow-up HCC developed in 32 (9%) of the 349 patients and decompensation was observed in 88 (28%) of 317 tumor-free patients. Five years after diagnosis, the probability of HCC appearance was 6% and the probability of decompensation was 23%. After the first episode of decompensation the probability of survival was 35% at 5 years. Cox's regression analysis identified three variables that independently correlated with HCC: age, serum levels of platelets, and liver firmness on physical examination. HBV (HBeAg or HBV-DNA) and HDV (anti-HDV) markers at presentation had no prognostic value for the development of HCC. In conclusion, a high proportion of patients with HBsAg-positive compensated cirrhosis do not experience worsening of their condition for several years, but once decompensation occurs life expectancy is poor. European, white patients with compensated cirrhosis type B are at consistent risk for HCC. Prognostic factors for HCC reflect an advanced stage of cirrhosis and support the hypothesis that development of a tumor could be the likely consequence of long-standing hepatic disease.

References (25)

  • RP Beasley

    Hepatitis B virus

  • L Bianchi et al.

    Acute and chronic hepatitis revisited

    Lancet

    (1977)
  • Cited by (391)

    • Natural History of Incidental Enhancing Nodules on Cone-Beam Computed Tomography during Transarterial Therapy of Hepatocellular Carcinoma

      2021, Journal of Vascular and Interventional Radiology
      Citation Excerpt :

      The presence of an IEN as a predictor of HCC development at other sites was not statistically significant. The incidence of developing HCC in the setting of liver cirrhosis ranges between 2.5% and 6.6% annually and is independent of treatment efficacy for previous HCC (14–16). It is not uncommon to encounter small enhancing nodules during imaging for locoregional therapy that raises suspicion for de novo HCC arising in the presence of homologous risk factors.

    View all citing articles on Scopus

    Supported in part by a contract (MR4-0190/NL) from the European Commission.

    View full text